{
    "hands_on_practices": [
        {
            "introduction": "Understanding the antihypertensive action of an ACE inhibitor begins at the molecular level, where the drug modulates the Renin-Angiotensin System. Instead of directly causing an effect, these drugs work by inhibiting a biological process; this exercise explores that concept using an indirect response model. You will quantify how drug concentration reduces the rate of Angiotensin II formation, the key pressor hormone in this pathway .",
            "id": "4577466",
            "problem": "A central pressor hormone in the renin–angiotensin system is Angiotensin II (Ang II). Angiotensin-Converting Enzyme (ACE) catalyzes the conversion of Angiotensin I (Ang I) to Ang II, and Ang II is eliminated by downstream processes that, at the pharmacodynamic (PD) level, can be lumped into a first-order loss. Consider an indirect response model for Ang II in which the production (input) term is driven by ACE catalysis and the loss (output) term is linear in Ang II concentration. Assume the following foundational bases:\n\n- At the PD level, Ang II dynamics can be represented by a production–loss form, with production proportional to the active ACE catalytic rate constant and loss represented by a first-order rate constant.\n- The pharmacological inhibition of ACE by an ACE inhibitor with plasma concentration $C$ can be described by a standard inhibitory maximal-effect model with $I_{\\max} = 1$, that is, the inhibitory effect (fractional inhibition) is $I = \\frac{C}{IC_{50} + C}$, where $IC_{50}$ is the inhibitor concentration that produces one-half of maximal inhibition.\n- The fraction of active enzyme is reduced by the fractional inhibition $I$, so the fraction of active ACE catalytic capacity is $1 - I$.\n\nStarting from these bases, derive the indirect response differential equation for Ang II concentration, explicitly showing how the effective ACE catalytic rate constant enters the production term via the factor $1 - I$. Then, define the fractional reduction in Ang II formation rate relative to baseline as the ratio of the decrease in the production term to the baseline production term, and compute this fractional reduction for an ACE inhibitor with concentration $C = 53 \\text{ nM}$ and $IC_{50} = 12 \\text{ nM}$. Express the fractional reduction as a decimal fraction, and round your answer to four significant figures. No units should be included in the final reported value.",
            "solution": "The problem requires the derivation of an indirect response model for Angiotensin II (Ang II) dynamics under the influence of an ACE inhibitor, and the calculation of the fractional reduction in Ang II formation for a given inhibitor concentration.\n\nLet the concentration of Angiotensin II be denoted by the variable $A_{II}$. The dynamics of $A_{II}$ are described by a production-loss differential equation of the general form:\n$$\n\\frac{dA_{II}}{dt} = \\text{Production Rate} - \\text{Loss Rate}\n$$\nThe problem states that the loss of Ang II is a first-order process. Therefore, the loss rate is proportional to the current concentration of Ang II, which can be written as $k_{out} A_{II}$, where $k_{out}$ is the first-order elimination rate constant.\n\nThe production of Ang II is catalyzed by the enzyme ACE. The production rate, which we denote as $k_{in}$, is proportional to the active ACE catalytic capacity. In the absence of any inhibitor (at baseline), the production rate is a constant, $k_{in,0}$.\n\nThe ACE inhibitor, with plasma concentration $C$, reduces the activity of the ACE enzyme. The fractional inhibition, $I$, is described by a standard maximal-effect model with $I_{\\max} = 1$:\n$$\nI = \\frac{C}{IC_{50} + C}\n$$\nwhere $IC_{50}$ is the inhibitor concentration that produces $50\\%$ of the maximal inhibition.\n\nAccording to the problem statement, the fraction of active ACE catalytic capacity is $(1 - I)$. Since the production rate of Ang II is proportional to the active ACE capacity, the production rate in the presence of the inhibitor, $k_{in}(C)$, is the baseline production rate $k_{in,0}$ multiplied by this active fraction:\n$$\nk_{in}(C) = k_{in,0} (1 - I)\n$$\nSubstituting the expression for $I$, we explicitly show how the production term is modulated by the inhibitor:\n$$\nk_{in}(C) = k_{in,0} \\left(1 - \\frac{C}{IC_{50} + C}\\right)\n$$\nThis expression can be simplified:\n$$\n1 - \\frac{C}{IC_{50} + C} = \\frac{(IC_{50} + C) - C}{IC_{50} + C} = \\frac{IC_{50}}{IC_{50} + C}\n$$\nSo, the effective production rate is $k_{in}(C) = k_{in,0} \\frac{IC_{50}}{IC_{50} + C}$.\n\nCombining the derived production term and the given loss term, the complete indirect response differential equation for Ang II concentration is:\n$$\n\\frac{dA_{II}}{dt} = k_{in,0} (1 - I) - k_{out} A_{II}\n$$\nor, written explicitly in terms of $C$:\n$$\n\\frac{dA_{II}}{dt} = k_{in,0} \\left(\\frac{IC_{50}}{IC_{50} + C}\\right) - k_{out} A_{II}\n$$\nThis completes the first part of the task.\n\nNext, we must define and compute the fractional reduction in Ang II formation rate relative to baseline. The problem defines this quantity as the ratio of the decrease in the production term to the baseline production term.\n\nThe baseline production term corresponds to the inhibitor concentration $C=0$. At $C=0$, the fractional inhibition $I=0$, so the baseline production rate is $k_{in}(0) = k_{in,0}(1-0) = k_{in,0}$.\n\nThe production term in the presence of the inhibitor at concentration $C$ is $k_{in}(C) = k_{in,0}(1-I)$.\n\nThe decrease in the production term is the difference between the baseline rate and the inhibited rate:\n$$\n\\text{Decrease} = k_{in,0} - k_{in}(C) = k_{in,0} - k_{in,0}(1-I) = k_{in,0} - k_{in,0} + k_{in,0}I = k_{in,0}I\n$$\nThe fractional reduction ($FR$) is therefore:\n$$\nFR = \\frac{\\text{Decrease}}{\\text{Baseline Production}} = \\frac{k_{in,0}I}{k_{in,0}} = I\n$$\nThis shows that the fractional reduction in the Ang II formation rate is identical to the fractional inhibition, $I$.\n\nFinally, we compute this value using the given data: $C = 53 \\text{ nM}$ and $IC_{50} = 12 \\text{ nM}$.\n$$\nFR = I = \\frac{C}{IC_{50} + C} = \\frac{53}{12 + 53} = \\frac{53}{65}\n$$\nPerforming the division to obtain a decimal fraction:\n$$\nFR = \\frac{53}{65} \\approx 0.8153846...\n$$\nThe problem requires the answer to be rounded to four significant figures. The fifth significant digit is $8$, so we round up the fourth digit.\n$$\nFR \\approx 0.8154\n$$",
            "answer": "$$\\boxed{0.8154}$$"
        },
        {
            "introduction": "While inhibiting Angiotensin II is the mechanism, clinicians measure success by the change in blood pressure. This practice bridges that gap by applying the widely used inhibitory $E_{\\max}$ model, a cornerstone of pharmacodynamics . By working with hypothetical clinical data, you will formulate this model and use it to estimate a drug's potency ($EC_{50}$), a critical parameter describing its concentration-response relationship.",
            "id": "4577483",
            "problem": "A patient with stage 2 hypertension is initiated on an Angiotensin-Converting Enzyme (ACE) inhibitor. For both ACE inhibitors and Angiotensin II Type 1 Receptor Blockers (ARBs), the pharmacodynamic effect on mean arterial pressure is commonly modeled as a saturable, immediate (no delay) transduction of target engagement. Assume the following foundational principles:\n\n- Under rapid equilibrium and a Hill coefficient of $1$, the fractional target engagement is a hyperbolic function of concentration $C$ with a characteristic concentration parameter $EC_{50}$ that yields half-maximal effect.\n- The pharmacodynamic response is a reduction in mean arterial pressure from a baseline $E_{0}$, with a maximal achievable reduction of $E_{\\max}$ when the pathway is fully engaged.\n\nIn a single subject study, the untreated baseline mean arterial pressure is $E_{0} = 120$ mmHg. Prior titration data in this patient indicate a maximal sustainable reduction of $E_{\\max} = 30$ mmHg for this mechanism. At two different oral dosing regimens that yield steady, unbound plasma concentrations of the active ACE-inhibiting species equal to $C = 10$ nM and $C = 60$ nM, the measured mean arterial pressures after effect equilibration are $110$ mmHg and $97.5$ mmHg, respectively.\n\nTasks:\n1. Starting from the above principles and without invoking any unproven shortcuts, formulate the direct saturable effect model that links the observed mean arterial pressure $E$ to concentration $C$, baseline $E_{0}$, the maximal reduction $E_{\\max}$, and the potency parameter $EC_{50}$.\n2. Using the two concentration–effect data pairs and the formulated model, estimate $EC_{50}$.\n\nRound your final numerical estimate of $EC_{50}$ to four significant figures. Express your answer in nM.",
            "solution": "The problem presented is a standard exercise in quantitative clinical pharmacology and is validated as scientifically grounded, well-posed, and containing sufficient and consistent information to derive a unique solution.\n\nThe solution is approached in two parts as requested: first, the formulation of the pharmacodynamic model, and second, the estimation of the model parameter $EC_{50}$ using the provided experimental data.\n\n**1. Formulation of the Pharmacodynamic Model**\n\nThe problem asks for a model linking the observed mean arterial pressure, $E$, to the drug concentration, $C$, based on fundamental principles of receptor theory and pharmacodynamics.\n\nFirst, we model the fractional target engagement. It is stated that receptor binding is under rapid equilibrium and follows a hyperbolic relationship with a Hill coefficient of $1$. This is characteristic of single-site binding and is mathematically analogous to the Michaelis-Menten formulation. The fractional target engagement, which represents the fraction of target receptors occupied by the drug at a given concentration $C$, is given by:\n$$\n\\text{Fractional Engagement} = \\frac{C}{EC_{50} + C}\n$$\nHere, $EC_{50}$ is the concentration of the drug that produces $50\\%$ of the maximal effect, which corresponds to $50\\%$ target engagement in this direct-link model.\n\nNext, we relate this fractional engagement to the observed pharmacodynamic response. The response is defined as the reduction in mean arterial pressure from its baseline value, $E_0$. We denote the observed pressure at concentration $C$ as $E(C)$. The drug-induced effect, which is the magnitude of this reduction, is therefore $E_0 - E(C)$. This effect is stated to be directly proportional to the fractional target engagement, with a maximal possible reduction of $E_{\\max}$. Thus, we can write:\n$$\nE_0 - E(C) = E_{\\max} \\cdot (\\text{Fractional Engagement})\n$$\nSubstituting the expression for fractional engagement into this equation, we get:\n$$\nE_0 - E(C) = E_{\\max} \\frac{C}{EC_{50} + C}\n$$\nThis equation models the pressure *reduction* as a function of concentration. To obtain the model for the absolute measured pressure, $E(C)$, we rearrange the equation:\n$$\nE(C) = E_0 - E_{\\max} \\frac{C}{EC_{50} + C}\n$$\nThis is the required direct inhibitory saturable effect model, commonly known as an inhibitory $E_{\\max}$ model. It formally links the measured pressure $E$ to the drug concentration $C$ via the parameters $E_0$, $E_{\\max}$, and $EC_{50}$.\n\n**2. Estimation of the Potency Parameter, $EC_{50}$**\n\nWe are provided with the following data:\n- Baseline mean arterial pressure: $E_0 = 120$ mmHg\n- Maximal pressure reduction: $E_{\\max} = 30$ mmHg\n- Data pair 1: At a concentration $C_1 = 10$ nM, the measured pressure is $E_1 = 110$ mmHg.\n- Data pair 2: At a concentration $C_2 = 60$ nM, the measured pressure is $E_2 = 97.5$ mmHg.\n\nTo determine $EC_{50}$, we first rearrange the derived model to solve for this parameter. Let $\\Delta E(C) = E_0 - E(C)$ be the pressure reduction at concentration $C$. The model is:\n$$\n\\Delta E(C) = E_{\\max} \\frac{C}{EC_{50} + C}\n$$\nDividing both sides by $E_{\\max}$:\n$$\n\\frac{\\Delta E(C)}{E_{\\max}} = \\frac{C}{EC_{50} + C}\n$$\nTaking the reciprocal of both sides yields:\n$$\n\\frac{E_{\\max}}{\\Delta E(C)} = \\frac{EC_{50} + C}{C} = \\frac{EC_{50}}{C} + 1\n$$\nIsolating the term containing $EC_{50}$:\n$$\n\\frac{E_{\\max}}{\\Delta E(C)} - 1 = \\frac{EC_{50}}{C}\n$$\nFinally, multiplying by $C$ gives the expression for $EC_{50}$:\n$$\nEC_{50} = C \\left( \\frac{E_{\\max}}{\\Delta E(C)} - 1 \\right) = C \\left( \\frac{E_{\\max}}{E_0 - E(C)} - 1 \\right)\n$$\nWe can now use the two experimental data points to calculate $EC_{50}$.\n\nUsing the first data pair ($C_1 = 10$ nM, $E_1 = 110$ mmHg):\nThe pressure reduction is $\\Delta E_1 = E_0 - E_1 = 120 - 110 = 10$ mmHg.\nSubstituting into the equation for $EC_{50}$:\n$$\nEC_{50} = 10 \\left( \\frac{30}{10} - 1 \\right) = 10 (3 - 1) = 10 \\times 2 = 20 \\text{ nM}\n$$\n\nUsing the second data pair ($C_2 = 60$ nM, $E_2 = 97.5$ mmHg):\nThe pressure reduction is $\\Delta E_2 = E_0 - E_2 = 120 - 97.5 = 22.5$ mmHg.\nSubstituting into the equation for $EC_{50}$:\n$$\nEC_{50} = 60 \\left( \\frac{30}{22.5} - 1 \\right)\n$$\nWe can simplify the fraction $\\frac{30}{22.5} = \\frac{30}{45/2} = \\frac{60}{45} = \\frac{4}{3}$.\n$$\nEC_{50} = 60 \\left( \\frac{4}{3} - 1 \\right) = 60 \\left( \\frac{1}{3} \\right) = 20 \\text{ nM}\n$$\nBoth data points yield an identical value of $EC_{50} = 20$ nM. This consistency confirms that the data precisely fit the simple inhibitory $E_{\\max}$ model with the given parameters $E_0$ and $E_{\\max}$. The problem asks that the final numerical estimate be rounded to four significant figures. Therefore, the estimated value is $20.00$ nM.",
            "answer": "$$\\boxed{20.00}$$"
        },
        {
            "introduction": "The true power of quantitative pharmacology lies in its ability to guide clinical decisions, like switching medications due to side effects. This final hands-on practice is a capstone exercise, challenging you to integrate both pharmacokinetic and pharmacodynamic principles to achieve therapeutic equivalence . By calculating an equivalent ARB dose to replace an ACE inhibitor, you will apply a full PK/PD model to ensure consistent therapeutic effect for a patient.",
            "id": "4577471",
            "problem": "A patient with essential hypertension develops chronic dry cough while receiving an angiotensin-converting enzyme inhibitor (ACE inhibitor). Clinically, cough is attributed to increased bradykinin and substance P due to decreased degradation by angiotensin-converting enzyme, and angiotensin II receptor blockers (ARBs) do not increase bradykinin; therefore, switching from an ACE inhibitor to an ARB is considered. Under the assumptions below, compute the once-daily ARB dose that achieves pharmacodynamic (PD) equivalence in mean arterial pressure reduction to the observed effect under the current ACE inhibitor regimen.\n\nAssumptions and given parameters:\n- Use the average steady-state free plasma concentration as the PD driver.\n- Pharmacokinetics (PK) are linear with first-order elimination; oral dosing every $\\tau$ hours produces a steady-state average total concentration proportional to input rate over clearance.\n- The free drug hypothesis holds: the effect is driven by the unbound plasma concentration, with $C_{f} = f_{u} \\times C_{\\text{total}}$.\n- The PD model for antihypertensive effect is the hyperbolic maximum effect model with class-specific parameters, where the mean arterial pressure reduction $E$ satisfies a saturable relationship in the free concentration and is monotonic in $C_{f}$.\n- Ignore active metabolites and time-dependent changes in clearance or receptor sensitivity over the dosing interval.\n\nACE inhibitor regimen and PD parameters:\n- Oral dose $D_{\\mathrm{ACE}} = 20\\ \\text{mg}$ once daily.\n- Oral bioavailability $F_{\\mathrm{ACE}} = 0.5$.\n- Apparent systemic clearance $CL_{\\mathrm{ACE}} = 5\\ \\text{L} \\cdot \\text{h}^{-1}$.\n- Dosing interval $\\tau = 24\\ \\text{h}$.\n- Fraction unbound in plasma $f_{u,\\mathrm{ACE}} = 0.1$.\n- Class PD: $E_{\\max,\\mathrm{ACE}} = 25\\ \\text{mmHg}$, $EC_{50,\\mathrm{ACE}} = 0.01\\ \\text{mg} \\cdot \\text{L}^{-1}$ (free).\n\nARB to be determined (once daily) and class PD parameters:\n- Oral bioavailability $F_{\\mathrm{ARB}} = 0.4$.\n- Apparent systemic clearance $CL_{\\mathrm{ARB}} = 2.5\\ \\text{L} \\cdot \\text{h}^{-1}$.\n- Dosing interval $\\tau = 24\\ \\text{h}$.\n- Fraction unbound in plasma $f_{u,\\mathrm{ARB}} = 0.05$.\n- Class PD: $E_{\\max,\\mathrm{ARB}} = 22\\ \\text{mmHg}$, $EC_{50,\\mathrm{ARB}} = 0.006\\ \\text{mg} \\cdot \\text{L}^{-1}$ (free).\n\nTask:\n- First, determine the mean arterial pressure reduction $E_{\\mathrm{ACE}}$ produced by the ACE inhibitor regimen under the above assumptions.\n- Then, compute the once-daily ARB oral dose $D_{\\mathrm{ARB}}$ that yields an equal reduction in mean arterial pressure, $E_{\\mathrm{ARB}} = E_{\\mathrm{ACE}}$, under the same assumptions.\n\nRound your final ARB dose to three significant figures. Express the final ARB dose in $\\mathrm{mg}$.",
            "solution": "The problem requires the calculation of an oral dose of an angiotensin II receptor blocker (ARB) that is pharmacodynamically equivalent to a given regimen of an angiotensin-converting enzyme (ACE) inhibitor. The process involves two main stages: first, determining the pharmacodynamic effect of the ACE inhibitor, and second, determining the ARB dose required to produce the same effect.\n\nThe analysis is based on established principles of pharmacokinetics (PK) and pharmacodynamics (PD). The key relationships are:\n\n1.  The average total drug concentration at steady state ($C_{\\mathrm{avg,total}}$) for a drug administered orally is given by:\n    $$C_{\\mathrm{avg,total}} = \\frac{F \\times D}{CL \\times \\tau}$$\n    where $D$ is the dose, $F$ is the oral bioavailability, $CL$ is the systemic clearance, and $\\tau$ is the dosing interval.\n\n2.  The free drug hypothesis states that the pharmacologic effect is driven by the unbound (free) concentration in plasma, $C_{f}$. The average steady-state free concentration, $C_{\\mathrm{avg,free}}$, is related to the total concentration by the fraction unbound, $f_u$:\n    $$C_{\\mathrm{avg,free}} = f_{u} \\times C_{\\mathrm{avg,total}}$$\n\n3.  The relationship between the free drug concentration and the pharmacodynamic effect, $E$ (mean arterial pressure reduction), is described by the hyperbolic maximum effect ($E_{\\max}$) model:\n    $$E = \\frac{E_{\\max} \\times C_{\\mathrm{avg,free}}}{EC_{50} + C_{\\mathrm{avg,free}}}$$\n    where $E_{\\max}$ is the maximum possible effect and $EC_{50}$ is the free concentration that produces $50\\%$ of the maximum effect.\n\nFirst, we calculate the effect of the ACE inhibitor regimen.\nThe given parameters for the ACE inhibitor are:\n$D_{\\mathrm{ACE}} = 20\\ \\text{mg}$\n$F_{\\mathrm{ACE}} = 0.5$\n$CL_{\\mathrm{ACE}} = 5\\ \\text{L} \\cdot \\text{h}^{-1}$\n$\\tau = 24\\ \\text{h}$\n$f_{u,\\mathrm{ACE}} = 0.1$\n$E_{\\max,\\mathrm{ACE}} = 25\\ \\text{mmHg}$\n$EC_{50,\\mathrm{ACE}} = 0.01\\ \\text{mg} \\cdot \\text{L}^{-1}$\n\nThe average total steady-state concentration of the ACE inhibitor is:\n$$C_{\\mathrm{avg,total,ACE}} = \\frac{F_{\\mathrm{ACE}} \\times D_{\\mathrm{ACE}}}{CL_{\\mathrm{ACE}} \\times \\tau} = \\frac{0.5 \\times 20\\ \\text{mg}}{5\\ \\text{L} \\cdot \\text{h}^{-1} \\times 24\\ \\text{h}} = \\frac{10}{120}\\ \\text{mg} \\cdot \\text{L}^{-1} = \\frac{1}{12}\\ \\text{mg} \\cdot \\text{L}^{-1}$$\n\nThe average free steady-state concentration is:\n$$C_{\\mathrm{avg,free,ACE}} = f_{u,\\mathrm{ACE}} \\times C_{\\mathrm{avg,total,ACE}} = 0.1 \\times \\frac{1}{12}\\ \\text{mg} \\cdot \\text{L}^{-1} = \\frac{1}{120}\\ \\text{mg} \\cdot \\text{L}^{-1}$$\n\nNow, we use this free concentration to compute the mean arterial pressure reduction, $E_{\\mathrm{ACE}}$:\n$$E_{\\mathrm{ACE}} = \\frac{E_{\\max,\\mathrm{ACE}} \\times C_{\\mathrm{avg,free,ACE}}}{EC_{50,\\mathrm{ACE}} + C_{\\mathrm{avg,free,ACE}}} = \\frac{25 \\times \\frac{1}{120}}{0.01 + \\frac{1}{120}} = \\frac{\\frac{25}{120}}{\\frac{1}{100} + \\frac{1}{120}} = \\frac{\\frac{25}{120}}{\\frac{120+100}{12000}} = \\frac{\\frac{25}{120}}{\\frac{220}{12000}} = \\frac{25}{120} \\times \\frac{12000}{220} = \\frac{25 \\times 100}{220} = \\frac{250}{22} = \\frac{125}{11}\\ \\text{mmHg}$$\n\nThe effect from the ACE inhibitor is a pressure reduction of $\\frac{125}{11}\\ \\text{mmHg}$, which is approximately $11.36\\ \\text{mmHg}$.\n\nNext, we find the ARB dose that produces an equivalent effect, $E_{\\mathrm{ARB}} = E_{\\mathrm{ACE}}$.\nThe given parameters for the ARB are:\n$F_{\\mathrm{ARB}} = 0.4$\n$CL_{\\mathrm{ARB}} = 2.5\\ \\text{L} \\cdot \\text{h}^{-1}$\n$\\tau = 24\\ \\text{h}$\n$f_{u,\\mathrm{ARB}} = 0.05$\n$E_{\\max,\\mathrm{ARB}} = 22\\ \\text{mmHg}$\n$EC_{50,\\mathrm{ARB}} = 0.006\\ \\text{mg} \\cdot \\text{L}^{-1}$\n\nThe target effect is $E_{\\mathrm{ARB}} = \\frac{125}{11}\\ \\text{mmHg}$. Since this is less than $E_{\\max,\\mathrm{ARB}} = 22\\ \\text{mmHg}$, it is possible to achieve this effect. We must first find the required free concentration of the ARB, $C_{\\mathrm{avg,free,ARB}}$, by rearranging the $E_{\\max}$ model equation:\n$E_{\\mathrm{ARB}} \\times (EC_{50,\\mathrm{ARB}} + C_{\\mathrm{avg,free,ARB}}) = E_{\\max,\\mathrm{ARB}} \\times C_{\\mathrm{avg,free,ARB}}$\n$E_{\\mathrm{ARB}} \\times EC_{50,\\mathrm{ARB}} = (E_{\\max,\\mathrm{ARB}} - E_{\\mathrm{ARB}}) \\times C_{\\mathrm{avg,free,ARB}}$\n$$C_{\\mathrm{avg,free,ARB}} = \\frac{E_{\\mathrm{ARB}} \\times EC_{50,\\mathrm{ARB}}}{E_{\\max,\\mathrm{ARB}} - E_{\\mathrm{ARB}}}$$\nSubstituting the values:\n$$C_{\\mathrm{avg,free,ARB}} = \\frac{\\frac{125}{11} \\times 0.006}{22 - \\frac{125}{11}} = \\frac{\\frac{125}{11} \\times \\frac{6}{1000}}{\\frac{242-125}{11}} = \\frac{\\frac{750}{11000}}{\\frac{117}{11}} = \\frac{750}{11000} \\times \\frac{11}{117} = \\frac{750}{1000 \\times 117} = \\frac{75}{11700} = \\frac{1}{156}\\ \\text{mg} \\cdot \\text{L}^{-1}$$\n\nNext, we calculate the required total concentration of the ARB:\n$$C_{\\mathrm{avg,total,ARB}} = \\frac{C_{\\mathrm{avg,free,ARB}}}{f_{u,\\mathrm{ARB}}} = \\frac{\\frac{1}{156}\\ \\text{mg} \\cdot \\text{L}^{-1}}{0.05} = \\frac{\\frac{1}{156}}{\\frac{1}{20}}\\ \\text{mg} \\cdot \\text{L}^{-1} = \\frac{20}{156}\\ \\text{mg} \\cdot \\text{L}^{-1} = \\frac{5}{39}\\ \\text{mg} \\cdot \\text{L}^{-1}$$\n\nFinally, we calculate the required oral dose, $D_{\\mathrm{ARB}}$, by rearranging the steady-state concentration formula:\n$$D_{\\mathrm{ARB}} = \\frac{C_{\\mathrm{avg,total,ARB}} \\times CL_{\\mathrm{ARB}} \\times \\tau}{F_{\\mathrm{ARB}}}$$\nSubstituting the known values:\n$$D_{\\mathrm{ARB}} = \\frac{(\\frac{5}{39}\\ \\text{mg} \\cdot \\text{L}^{-1}) \\times (2.5\\ \\text{L} \\cdot \\text{h}^{-1}) \\times (24\\ \\text{h})}{0.4} = \\frac{\\frac{5}{39} \\times 60}{0.4}\\ \\text{mg} = \\frac{\\frac{300}{39}}{0.4}\\ \\text{mg} = \\frac{300}{39 \\times 0.4}\\ \\text{mg} = \\frac{300}{15.6}\\ \\text{mg} = \\frac{3000}{156}\\ \\text{mg}$$\nSimplifying the fraction:\n$$D_{\\mathrm{ARB}} = \\frac{3000 \\div 12}{156 \\div 12}\\ \\text{mg} = \\frac{250}{13}\\ \\text{mg}$$\n\nAs a decimal, this is $D_{\\mathrm{ARB}} \\approx 19.230769...\\ \\text{mg}$. The problem requires rounding the final answer to three significant figures.\n$$D_{\\mathrm{ARB}} \\approx 19.2\\ \\text{mg}$$",
            "answer": "$$\\boxed{19.2}$$"
        }
    ]
}